Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes is a research paper published in Diabetes Care (2022). On theSindex it has a DataRank of 2.5. It has been cited 78 times, with 71 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph β no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full β never from an abstract alone.
Base Score Contribution
0.655
From this paper's citation signal
Citation Network Contribution
1.8
From 57 citing papers with measurable signal
Ranked by each citer's contribution to N(p) β log1p(Cq) divided by its reference count β out of 71 citers.
NHLBI NIH HHS
Grant: R21 HL150268
National Institutes of Health
Grant: 1R21HL150268-01
Role of Methionine Sulfoxide and Advanced Glycation Endproducts in Cardiovascular and Renal Complications of Type 2 Diabetes
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
Additional file 1 of SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
Additional file 2 of SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
Additional file 2 of SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway